重庆智翔金泰生物制药股份有限公司2025年年度业绩预告

Core Viewpoint - The company, Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd., forecasts significant growth in revenue for the year 2025, alongside a reduction in research and development expenses, while still expecting a net loss that is less severe than the previous year [2][7]. Group 1: Performance Forecast - The company anticipates 2025 annual revenue between 209.45 million and 250.88 million yuan, representing an increase of 179.35 million to 220.78 million yuan compared to the previous year, with a year-on-year growth rate of 595.96% to 733.62% [2]. - Expected R&D expenses for 2025 are projected to be between 425.21 million and 519.70 million yuan, a decrease of 90.09 million to 184.58 million yuan from the previous year, reflecting a year-on-year reduction of 14.77% to 30.27% [2]. - The forecasted net loss attributable to the parent company for 2025 is estimated to be between 480.64 million and 587.45 million yuan, which is a reduction of 209.83 million to 316.64 million yuan compared to the previous year, indicating a year-on-year decrease of 26.32% to 39.71% [2]. - The net loss attributable to the parent company after deducting non-recurring gains and losses is expected to be between 523.63 million and 630.44 million yuan, with a reduction of 173.89 million to 280.70 million yuan compared to the previous year, reflecting a year-on-year decrease of 21.62% to 34.90% [2]. Group 2: Previous Year Performance - In 2024, the company achieved a revenue of 30.10 million yuan [3]. - The R&D expenses for 2024 were recorded at 609.79 million yuan [4]. - The net loss attributable to the parent company for 2024 was 797.27 million yuan [5]. - The net loss attributable to the parent company after deducting non-recurring gains and losses for 2024 was 804.33 million yuan [6]. Group 3: Reasons for Performance Changes - The significant increase in revenue is attributed to the steady growth in sales of the company's first commercial product, the Saliqi monoclonal antibody injection, and the recognition of licensing income from the GR1803 injection licensing agreement [7]. - The company has maintained high levels of R&D investment while advancing multiple projects into clinical research stages, with core products entering critical clinical trial phases. The absence of share-based payment expenses in 2025, due to the completion of the stock incentive plan for the core team in 2024, has also contributed to the reduction in expenses [7].